Mapping Refinement: Institutional Survey Explores Transition to Oral Tamoxifen
Published: 1 April 2024
In April 2024, the Culture of Care Committee conducted an institutional survey to evaluate tamoxifen administration practices. With 32 responses across all research roles, the findings revealed that while IP injection remains the standard, over half of researchers observed adverse effects like weight loss. The survey established a clear roadmap for refinement, identifying that shared validation data and technical support are key to helping groups transition to oral methods.
Tamoxifen administration is a routine but potentially impactful procedure for laboratory animals. Exploring refined approaches, such as oral administration, has the potential to reduce adverse effects, improve animal welfare and support more consistent scientific outcomes. Understanding the practical barriers to change could allow targeted support to be developed, helping research groups adopt refinements confidently and responsibly moving forward.
To this end, in April 2024, we ran a survey to explore current practices, challenges and readiness for transitioning to oral tamoxifen administration across research groups. The survey received 32 responses from a mix of roles, including principal investigators, postdoctoral researchers, PhD students and professional services staff, providing a broad cross-section of institutional practice.
Responses showed that intraperitoneal (IP) injection remains the predominant method of tamoxifen administration, while oral approaches are currently used by only a small number of groups. A key driver for interest in alternative methods was animal welfare: over half of respondents reported clinically notable adverse effects following tamoxifen dosing, most commonly weight loss, highlighting that we could see widespread potential benefits through refinement.
Encouragingly, there was clear support for exploring oral administration. Participants identified well-defined protocols, access to validation and pilot data, and practical training and technical support as the main enablers for change. Many respondents also emphasised the importance of direct comparisons between IP and oral methods, including confirmation of gene suppression, phenotype and off-target effects, to build confidence in adoption.
Overall, the survey highlighted strong interest in oral tamoxifen as a refinement opportunity. While technical and resource-related barriers remain, the findings provide a clear roadmap for how targeted support, shared evidence and collaborative pilot work could help facilitate a transition and further strengthen a culture of care.
First published: 1 April 2024